• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

NextCell Pharma

1.11 SEK

-4.48 %

Less than 1K followers

NXTCL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.48 %
+5.71 %
-14.62 %
+51.85 %
+50.82 %
+2.97 %
-66.38 %
-91.38 %
-49.81 %

NextCell Pharma is a Swedish clinical-stage cell therapy company developing treatments for immune-mediated diseases, with the company's most recent candidate being a type 1 diabetes candidate. The company's platform, NXTCL™, is designed to enable cell therapies with consistent efficacy, scalable manufacturing and the potential to change the course of the disease. NextCell is headquartered in Huddinge.

Read more
Market cap
140.3M SEK
Turnover
137.57K SEK
Revenue
10.94M
EBIT %
-328.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
Results are out. The report is still messy and incomplete. CEO comments are conspicuous by their absence, etc. This started in the previous quarterly report after the CFO left. Apparently, the new CFO has not fixed the issue. The report covers an exceptional 16-month financial year...
2/26/2026, 9:11 AM
5
New press release and the stock is showing new momentum, up 12% today. For the sharp-eyed, however, this isn’t new information, because even though Nextcell hasn’t communicated this directly to investors, yours truly spotted this 29 days ago in this discussion.
2/18/2026, 2:11 PM
5
Interesting questions that I have also been pondering. Is the internal funding from Cellaviva and Qvance etc. sufficient? I remember the CEO stating in some presentation that Qvance would reach profitability by the end of the current year. Cell and tissue sales haven’t grown very...
2/14/2026, 8:48 AM
by Timo Rousi
4
Diamyd apparently owns about 15% of NextCell. Diamyd plummeted 90% today, and now there’s likely concern they’ll dump their NextCell shares due to a cash crunch. NextCell has dropped about 15% today. What are your thoughts on the situation? Is there also a slight worry creeping in...
3/30/2026, 7:45 AM
by Expaco_b
3
Trading volume has picked up today, and about 3 million shares have already been traded in an hour. The stock is now at that one krona mark; it’s easy to guess that Diamyd has finalized its next steps and is now selling off its holdings. According to AI, they had about 5 million ...
4/28/2026, 8:17 AM
by Expaco_b
2
The company is truly an extreme example of poor liquidity for a listed company. Last Friday at the open: 10:03 share 1.68 (+7%) 10:05 share 1.51 (-4%) Today the range was even wider. At the open, it rose +9.5%, and a couple of minutes later, it dipped to -5.5%. Hardly any trades ...
2/23/2026, 12:23 PM
2
Now the valuation has doubled, and rising revenue can, with some luck, justify it as well. Haven’t investors sufficiently accounted for the potential of these subsidiaries’ operations? I don’t believe they’ve been given much weight, as not a single euro has been seen yet. The company...
2/17/2026, 2:03 PM
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8
2026

Interim report Q2'26

26.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Regulatory press release5/28/2026, 5:45 AM

NextCell Pharma AB: Interim Report first quarter 2026

NextCell Pharma
Regulatory press release5/27/2026, 12:00 PM

NextCell Pharma AB (publ) Annual General Meeting 2026

NextCell Pharma
Press release5/6/2026, 8:50 AM

NextCell Pharma AB: NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

NextCell Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/4/2026, 5:45 AM

NextCell Pharma AB: NextCell Pharma publishes Annual Report 2024/2024

NextCell Pharma
Press release3/13/2026, 12:00 PM

NextCell Pharma AB: ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy

NextCell Pharma
Press release3/4/2026, 9:59 AM

Redeye: NextCell Pharma (year-end report review): Making progress

NextCell Pharma
Press release3/3/2026, 9:00 AM

NextCell Pharma AB: NextCell Pharma presents historical quarterly figures

NextCell Pharma
Regulatory press release2/26/2026, 6:30 AM

NextCell Pharma AB: NextCell publishes Year-End Report 2024/2025

NextCell Pharma
Press release2/17/2026, 8:45 AM

NextCell Pharma AB: NextCell Participating in JETRO's Japan Entry Acceleration Program

NextCell Pharma
Press release2/3/2026, 9:00 AM

NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes

NextCell Pharma
Press release1/21/2026, 1:00 PM

NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma
Regulatory press release1/21/2026, 10:30 AM

NextCell Pharma AB: NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

NextCell Pharma
Regulatory press release1/21/2026, 6:45 AM

NextCell Pharma AB: NextCell decides to propose a directed share issue of SEK 15 million

NextCell Pharma
Press release12/9/2025, 6:45 AM

NextCell Pharma AB: NextCell in Swedish Life Science Delegation to Hong Kong

NextCell Pharma
Press release12/2/2025, 6:45 AM

NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations

NextCell Pharma
Regulatory press release11/20/2025, 7:45 AM

NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO

NextCell Pharma
Press release11/19/2025, 7:45 AM

NextCell Pharma AB: NextCell Pharma company presentations

NextCell Pharma
Press release11/19/2025, 7:13 AM

BioStock: Video from Nextcell Pharma's presentation at BioStock Life Science Summit 2025

NextCell Pharma
Press release11/7/2025, 7:44 AM

Redeye: NextCell Pharma (Q4 2024/2025 update) - ProTrans-Young readout in Q3 2026

NextCell Pharma
Regulatory press release10/30/2025, 6:30 AM

NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025

NextCell Pharma